Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT05320692
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
- NCT05320692 ↗
- Active, not recruiting
- Jiangsu HengRui Medicine Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TACE+Camrelizumab+Apatinib mesylate; TACE
- Arms
- Treatment group · Experimental
- Control group · Active comparator
- Enrollment
- 423
- Primary outcomes
- PFS assessed by BIRC
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Start
- Aug 9, 2022
- Primary completion
- Jul 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05320692 · updated Dec 11, 2025